The JAG1 Knockout PaTu 8988t Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population that disrupts JAG1, encoding the Notch ligand Jagged1, in the PaTu 8988t pancreatic adenocarcinoma cell line. This loss-of-function model abolishes Jagged1 expression to study Jagged1-dependent Notch signaling. The polyclonal nature maintains cellular heterogeneity, avoiding biases from clonal isolation and providing a realistic tumor cell context for gene-function analyses.
PaTu 8988t is a well-differentiated epithelial pancreatic cancer cell line derived from a liver metastasis. It retains oncogenic KRAS signaling and proliferative capacity, making it a standard model for pancreatic ductal adenocarcinoma research. The metastatic origin and epithelial phenotype are well-suited for investigating Jagged1’s roles in tumor growth, metastasis, and EMT, and the line’s established use in drug assays supports translational applications.
Jagged1 is a transmembrane ligand for NOTCH1?C4 receptors, and upon binding initiates ADAM10/17 and PSEN1-mediated proteolysis to release NICD. NICD complexes with RBPJ and MAML to activate transcription of HES1, HEY1, MYC, CCND1, and EMT drivers SNAI1/SNAI2. Jagged1 is regulated by TGFB1, HIF1A, KRAS, and NF-??B, and interacts with MIB1. JAG1 disruption silences this pathway, allowing dissection of Notch effects on proliferation and migration.
JAG1 overexpression in pancreatic cancer is linked to aggressiveness and drug resistance. This polyclonal knockout enables evaluation of how JAG1 loss alters proliferation, apoptosis, and invasion. It also facilitates investigation of pathway crosstalk, such as between Notch and KRAS or TGF??, in a heterogeneous cell population that mirrors tumor complexity. Such studies can reveal adaptive mechanisms and inform therapeutic strategies.
Applications include Notch pathway analysis, tumor microenvironment studies, and drug resistance screening in PDAC. Compatible assays cover Western blotting, RT-qPCR, RNA-seq, flow cytometry, co-immunoprecipitation, and functional assays for proliferation, apoptosis, migration, and drug sensitivity. The polyclonal knockout is ideal for compound screening and exploring resistance. For further information, contact Ascent Research.
